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Abstract
Background —High-sensitivity cardiac troponin assays enable myocardial infarction to be ruled 
out earlier, but the optimal approach is uncertain. We compared the European Society of
Cardiology (ESC) rule-out pathway, with a pathway that incorporates lower cardiac troponin 
concentrations to risk stratify patients.
Methods —Patients with suspected acute coronary syndrome (n=1,218) underwent high-
sensitivity cardiac troponin I measurement at presentation, 3 and 6 or 12 hours. We compared the 
ESC pathway (<99th centile at presentation, or at 3 hours if symptoms <6 hours) with a pathway 
developed in the High-Sensitivity Troponin in the Evaluation of patients with Acute Coronary 
Syndrome (High-STEACS) study population (<5 ng/L at presentation, or change <3 ng/L and
<99th centile at 3 hours). The primary outcome was a comparison of the negative predictive value 
(NPV) of both pathways for index type 1 myocardial infarction, or type 1 myocardial infarction 
or cardiac death at 30 days. We evaluated the primary outcome in pre-specified subgroups 
stratified by age, gender, time of symptom onset and known ischaemic heart disease. 
Results —The primary outcome occurred in 15.7% (191/1,218) patients. In those <99th centile at
presentation, the ESC pathway ruled out myocardial infarction in 28.1% (342/1,218) and 78.9% 
(961/1,218) at presentation and 3 hours respectively, missing 18 index and two 30-day events
(NPV 97.9%, 95% confidence intervals [CI] 96.9-98.7%). The High-STEACS pathway ruled out 
40.7% (496/1,218) and 74.2% (904/1,218) at presentation and 3 hours, missing two index and
two 30-day events (NPV 99.5%, 95% CI 99.0-99.9%; P<0.001 for comparison). The NPV of the
High-STEACS pathway was greater than the ESC pathway overall (P<0.001), and in all 
subgroups including those presenting early or known to have ischaemic heart disease.  
Conclusions—Use of the High-STEACS pathway incorporating low high-sensitivity cardiac 
troponin concentrations rules out myocardial infarction in more patients at presentation and 
misses 5-fold fewer index myocardial infarctions than guideline approved pathways based 
exclusively on the 99th centile.
Clinical Trial Registration—https://clinicaltrials.gov Identifier: NCT:01852123
Key-words: acute coronary syndrome; acute myocardial infarction; troponin; biomarker; high-
sensitivity assay
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Clinical Perspective
What is new? 
x The European Society of Cardiology (ESC) recommend high-sensitivity cardiac troponin 
assays to rule out myocardial infarction using a three-hour pathway based on the 99th
centile. 
x In this study of 1,218 patients, the ESC pathway had a negative predictive value (NPV) 
of 97.9% missing 18 index and two recurrent myocardial infarction.  
x We propose a new pathway using a high-sensitivity cardiac troponin I assay that 
incorporates a risk stratification threshold of <5 ng/L at presentation, and no change (<3 
ng/L) at three hours.  
x This pathway had a higher NPV than the ESC pathway at 99.5%, missing two index and 
two recurrent events.  
What are the clinical implications?
x  The 99th centile is not the optimal threshold to rule out myocardial infarction at 
presentation or at three hours, and pathways based exclusively on this threshold may miss 
patients with myocardial infarction. 
x Use of the High-STEACS pathway, incorporating a risk stratification threshold at 
presentation and recognising small but important changes in cardiac troponin within the 
normal reference range on serial testing, will minimise the risk of missed events.
x Importantly, the use of risk stratification thresholds identifies more patients as low risk at 
presentation, permitting a higher proportion of patients to be safely discharged. 
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Introduction
Chest pain is a frequent presenting symptom in patients attending the Emergency Department, 
with significant resource implications for healthcare providers.1 Whilst the majority of patients 
with chest pain do not have an acute myocardial infarction2, prompt and accurate exclusion of 
this diagnosis remains challenging in clinical practice, and often results in unnecessary hospital 
admission.3-5 Guidelines from the European Society of Cardiology (ESC) support the use of 
high-sensitivity cardiac troponins and earlier testing to rule out myocardial infarction where 
concentrations are <99th centile upper reference limit (URL) at presentation in those patients with 
symptoms for more than 6 hours, and at 3 hours in the remainder.6 A similar approach was 
recommended by the National Institute of Clinical Health and Excellence (NICE), although 
concerns were raised about the generalisability of the studies evaluating the effectiveness of this 
approach.7  
 Recent studies have demonstrated that very low cardiac troponin concentrations can help 
to further risk stratify patients.8-22 As such, the latest European guidelines include an additional 
one hour pathway incorporating lower thresholds of cardiac troponin for risk stratification.6 We 
recently demonstrated in consecutive patients with suspected acute coronary syndrome that a
cardiac troponin concentration <5 ng/L at presentation had a negative predictive value of 99.6% 
[95%CI 99.3–99.8] for myocardial infarction during the index presentation, or myocardial 
infarction or cardiac death at 30 days. Furthermore, patients with cardiac troponin concentrations 
<5 ng/L had very low rates of adverse cardiac events at one year.14
Whilst it is clear that high-sensitivity cardiac troponins enable myocardial infarction to be 
ruled out earlier, the optimal approach is uncertain. As such, we compared the safety and 
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efficacy of the ESC pathway based on the 99th centile alone, with our clinical pathway 
incorporating low cardiac troponin concentrations to risk stratify patients. 
Methods
Study population
Patients with suspected acute coronary syndrome were recruited from the Emergency 
Department of the Royal Infirmary of Edinburgh, a tertiary care hospital in Scotland, between 1st
June 2013 and 31st September 2015 into a sub-study of the High-Sensitivity Troponin in the 
Evaluation of patients with Acute Coronary Syndrome (High-STEACS) trial. All patients in 
whom the attending clinician requested cardiac troponin for suspected acute coronary syndrome 
were eligible for inclusion. We did not enrol patients with ST-segment elevation myocardial 
infarction, those who were unable to provide consent, or those from outside our region to ensure 
complete follow up. Blood samples were obtained at presentation and at 6-12 hours for high-
sensitivity cardiac troponin testing as part of routine clinical care. Patients provided written 
informed consent for additional sampling at 3 hours with the results of testing at this time-point 
not used to guide patient care. This pre-specified analysis was restricted to those patients where 
serial samples were available (Figure S1). This clinical trial was registered (NCT:01852123), 
approved by the national research ethics committee, and conducted in accordance with the 
Declaration of Helsinki.  
High-sensitivity cardiac troponin I assay
The Abbott ARCHITECTSTAT high-sensitive cardiac troponin I assay (Abbott Laboratories, 
Abbott Park, IL) is a two-step chemo-luminescent assay with a limit of detection of 1.2 ng/L and 
coefficient of variation of less than 10% at 6 ng/L.23 This assay performance has been 
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independently validated across multiple centres under routine laboratory working conditions, 
with a reported inter-laboratory coefficient of variation of 12.6% at 3.5 ng/L across 33 
instruments.14 The upper reference limit 99th centiles were determined in 4,590 samples from 
healthy individuals as 16 ng/L for women and 34 ng/L in men10, and from 10th December 2013 
onwards these thresholds were used in clinical practice.  
Baseline characteristics
Patient baseline characteristics, including chest pain characteristics, onset of symptoms, prior 
medical history, cardiovascular risk factors, medication, and clinical observations, in addition to 
investigations including serial 12-lead electrocardiography and cardiac imaging, were obtained 
from a dedicated case record form, patient questionnaire and the electronic patient record 
(TrakCare, InterSystems, Cambridge, MA). Hyperlipidaemia or hypertension were defined as a 
history of the condition, or by the use of lipid-lowering or anti-hypertensive therapies, 
respectively. Ischaemic heart disease was defined as a history of angina, prior myocardial 
infarction or prior coronary revascularization.
Diagnostic adjudication
The final diagnosis was adjudicated for all patients by two independent physicians (AC/AA), 
with consensus from a third physician (JA/NM) where there was discrepancy following review 
of all clinical information, both non-invasive and invasive investigations and outcomes from 
presentation to 30 days. Patients were classified as having type 1 myocardial infarction, type 2 
myocardial infarction or myocardial injury in accordance with the third universal definition of 
myocardial infarction as previously reported.6,14 Any cardiac troponin I concentration above the 
sex-specific 99th centile upper reference limit was considered evidence of myocardial necrosis. 
Type 1 myocardial infarction was defined as myocardial necrosis in the context of a presentation 
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with symptoms suggestive of acute coronary syndrome or evidence of myocardial ischemia. 
Patients with symptoms or signs of myocardial ischemia due to increased oxygen demand or 
decreased supply (e.g. tachyarrhythmia, hypotension or anaemia) secondary to an alternative 
pathology and myocardial necrosis were classified as type 2 myocardial infarction. Myocardial 
injury was defined as evidence of myocardial necrosis in the absence of any clinical features of 
myocardial ischaemia. Agreement for a diagnosis of type 1 myocardial infarction was very good 
(N= 0.82, 95%CI 0.75-0.89). 
Clinical outcomes
The primary outcome was a composite of index type 1 myocardial infarction, or type 1 
myocardial infarction or cardiac death at 30 days. We used regional and national registries in 
addition to individual patient follow up at 30 days to ensure follow up was complete for the 
entire study population. All subsequent events were adjudicated using the same approach as for 
the index presentation. TrakCare software application (InterSystems Corporation, Cambridge, 
MA, USA) is a regional electronic patient record system, which provides data on all hospital 
admissions to both tertiary or secondary care hospitals in the southeast of Scotland. All in-
hospital and community deaths are recorded in a comprehensive national database, the General 
Register of Scotland. Cardiac death was defined as any death due to myocardial infarction, 
arrhythmia or heart failure. 
Clinical pathways 
We compared the safety and efficacy of two pathways to rule out the composite outcome of 
index myocardial infarction, and myocardial infarction or cardiac death at 30 days (Figure 1).
The ESC pathway rules out myocardial infarction where cardiac troponin concentrations are 
<99th centile at presentation in patients with symptoms for more than 6 hours. In patients with 
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symptoms for less 6 hours, a second troponin measurement is performed 3 hours from 
presentation, with myocardial infarction ruled out if cardiac troponin remains <99th centile or is 
>99th centile without a significant change in concentration.6 Previously published guidance from 
the ESC Working Group on Acute Cardiac Care recommends use of a change in cardiac troponin 
concentration >50% of the 99th centile upper reference limit at 3 hours.24
We compared the ESC pathway to the High-STEACS pathway, based on our previous 
observations, that utilises a risk stratification threshold of 5 ng/L at presentation.14,25 This 
threshold has since been externally validated in separate populations, with a recent a multi-centre 
study across five independent cohorts finding a troponin concentration of <5 ng/L had a negative 
predictive value of 99.2% [95%CI 98.8-99.5%].15 In our pathway, patients with cardiac troponin 
concentrations <5 ng/L at presentation are considered low risk and myocardial infarction is ruled 
out without further testing, unless they present early with symptom onset <2 hours from 
presentation where cardiac troponin is retested 3 hours after presentation.14 Patients with cardiac 
WURSRQLQFRQFHQWUDWLRQVQJ/DWSUHVHQWDWLRQDUHUHWHVWHGDWKRXUV0\RFDUGLDOLQIDUFWLRQLV
ruled out at 3 hours if cardiac troponin concentrations are unchanged and remain <99th centile on 
retesting. A change in cardiac troponin concentration was defined as an increase or decrease 
ng/L at 3 hours, as this is the lowest measurable concentration within the normal reference range 
that exceeds analytical variation of the assay.26 This change in cardiac troponin concentration 
was internally and externally validated, using data from the APACE cohort (Table S1).  
Statistical analysis 
Baseline characteristics are summarised as mean (standard deviation, SD) or median (inter-
quartile range, IQR) as appropriate. Patients with maximal cardiac troponin concentrations th
centile were compared with those >99th centile using a chi-square test or Wilcoxon rank sum test.
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The primary outcome was the negative predictive value (NPV) of each pathway, using the 
composite endpoint of index type 1 myocardial infarction, or subsequent type 1 myocardial 
infarction or cardiac death at 30 days. As we estimated the NPV would approach 100%, we used 
a Bayesian approach with a Jeffrey’s prior (beta distribution with both shape parameters equal to 
0.5) as this is more robust when confidence intervals approach 0 or 1.27 We derived a weighted 
generalised score statistic to compare the NPV of the ESC and the High-STEACS pathway, as 
previously described.28 We evaluated the NPV in pre-specified subgroups stratified by time of 
symptom onset (<RU6 hours), DJHRU years), sex, and history of ischaemic heart 
disease. We determined absolute (hs-TnI3hr – hs-TnI0hr) and relative ([(hs-TnI3hr – hs-TnI0hr) / hs-
TnI0hr] x 100) change in cardiac troponin concentration from presentation to 3 hours, and
determined sensitivity, specificity and positive predictive value (PPV) with 95% confidence 
intervals (CI) using a Bayesian approach as per the NPV. In a sensitivity analysis, we evaluated 
the NPV for a primary outcome encompassing type 1 or type 2 myocardial infarction, or 
myocardial injury, or myocardial infarction or cardiac death at 30 days. To ensure our findings 
were generalizable to those centers that do not apply sex-specific diagnostic thresholds, we 
evaluated the performance of both pathways using a single 99th centile upper reference limit for 
men and women of 26 ng/L. A further sensitivity analysis evaluated the NPV in patients without 
evidence of myocardial LVFKDHPLDGHILQHGDVPP67-segment depression or new T-wave 
inversion) on the presenting electrocardiogram, who were considered intermediate or low risk 
with a GRACE score of <140.6 We evaluated pathway efficacy by determining the number of 
patients ruled out at 0 and 3 hours as a proportion of the total study population, with comparison 
by McNemar’s test for paired proportions. A two-sided P<0.05 was considered statistically 
significant. All analyses were performed using R (Version 3.2.2). 
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Results
We identified 1,218 patients with suspected acute coronary syndrome who met our inclusion and 
exclusion criteria (62.4±14.1 years, 61% male; Table 1, Figure S1). The adjudicated diagnosis 
was type 1 myocardial infarction in 15.5% (189/1,218), type 2 myocardial infarction in 5.5% 
(67/1,218) and myocardial injury in 2.1% (26/1,218). There were six subsequent type 1 
myocardial infarcts and six cardiac deaths at 30 days. At presentation, 216 patients had troponin 
concentrations >99th centile with 11.9% (145/1,218) type 1 and 3.8% (46/1,218) type 2 
myocardial infarction, and 2.1% (25/1,218) patients with myocardial injury.
ESC pathway  
The ESC pathway ruled out 28.1% (342/1,218) of patients at presentation and 78.9% (961/1,218) 
of all patients by 3 hours. However, this approach missed 18 index type 1 myocardial infarctions 
(four on presentation, fourteen at three hours) and two subsequent myocardial infarctions within 
30 days for an overall NPV of 97.9% [95% CI, 96.9-98.7%; Table 2, Figure 2]. The sensitivity of 
this pathway is 89.3% [95% CI, 84.9-93.5%], and a summary of the missed events is provided in 
Table S2.
High-STEACS pathway
In comparison, the High-STEACS pathway ruled out 40.7% (496/1,218) of patients at 
presentation, and 74.2% (904/1,218) of all patients by 3 hours. There were two missed index 
type 1 myocardial infarction (none at presentation, two at three hours) and two recurrent events
for an overall NPV of 99.5% [95% CI, 99.0-99.9]; Table 2, Figure 2). All events missed by the 
High-STEACS pathway were also missed by the ESC pathway. The sensitivity of the High-
STEACS pathway was 97.7% [95% CI, 95.5-99.5%] and a summary of missed events is 
provided in Table S3.  
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The High-STEACS pathway identifies more patients potentially suitable for discharge at 
presentation following a single cardiac troponin measurement compared to the ESC pathway 
(40.7% [95% CI, 38.0-43.5%] versus 28.1% [95% CI, 25.6-30.7%] respectively, P<0.001;
Figure 1). At three hours, the High-STEACS pathway ruled our fewer patients than the ESC 
pathway (74.2% [95% CI, 71.7-76.6%] versus 78.9% [95% CI, 76.5-81.1%], P<0.001). In the 57
patients ruled out at three hours by the ESC pathway but not the High-STEACS pathway, there 
were 13 missed index myocardial infarction (22.8%).  
The NPV of the High-STEACS pathway was greater than the ESC pathway overall 
(99.5% [95%CI 99.0-99.9] versus (97.9% [95%CI 96.9-98.9%]; P<0.001), and for all pre-
specified subgroups (Table 2, Figure 2). In the subgroup of patients who presented within three
hours of symptom onset there were more false negatives and the NPV was lower with the ESC 
pathway (9 false negatives, NPV 97.8% [95% CI, 96.2-99.0%]) than with the High-STEACS 
pathway (1 false negative, NPV 99.6% [95% CI, 98.8-100.0%]). Similar differences were 
apparent in those patients presenting within six hours of symptom onset (ESC versus High-
STEACS, NPV 97.5% [95% CI, 96.1-98.6%] versus 99.6% [95% CI, 98.9-99.9%]). In men, the 
NPV of the ESC pathway was lower than the High-STEACS pathway (97.4% [95% CI, 96.0-
98.5%] versus 99.4% [95% CI, 98.5-99.8%]), although both pathways performed similarly in 
women. The lowest NPV for both the ESC and the High-STEACS pathway was in the subgroup 
of patients known to have ischaemic heart disease (95.8% [95% CI, 93.6-97.6%] and 98.7%
[95% CI, 97.4-99.6%] respectively).  
In patients with an index type 1 myocardial infarction missed by the ESC pathway, the 
median change in cardiac troponin concentration between presentation and 3 hours was 5.5 ng/L 
(inter-quartile range [IQR] 4.0-13.3 ng/L). The majority of these patients (16/18) were not ruled 
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out at 3 hours by the High-STEACS pathway as the change in cardiac troponin concentration 
was QJ/(Table S4) and further testing at 6 hours is recommended. In an external validation 
cohort of 2,533 patients with suspected acute coronary syndrome (Table S1), a change in cardiac 
troponin concentration <3 ng/L at 3 hours ruled out 69.9% of those patients who required 
retesting (514/735), and missed no patients with an index diagnosis of type 1 myocardial 
infarction (Table S5). 
The specificity and PPV of the ESC pathway was greater than the High-STEACS 
pathway at three hours (specificity 91.6% [95% CI, 89.9-93.3] and PPV 66.5% [95% CI, 60.6-
72.1] versus specificity 87.6% [95% CI, 85.6-89.6%] and PPV 59.5% [95% CI, 54.1-64.9%], 
Table 2). However, the overall specificity and PPV of the High-STEACS pathway was 
comparable when patients requiring additional testing at 6 hours were included (specificity 
91.4% [95% CI, 89.7-93.1%] and PPV 67.9% [95% CI, 62.3-73.3%], Table S6). 
Sensitivity analyses 
In a sensitivity analysis, we evaluated both pathways using a single 99th centile upper reference 
limit for men and women of 26 ng/L. The performance of both pathways was similar, with a 
NPV of 97.7% [95% CI, 96.6-98.5%] for the ESC pathway (20 missed index type 1 myocardial 
infarction and two missed events at 30 days), and 99.4% [95% CI, 98.8-99.8%] for the High-
STEACS pathway (three missed index type 1 myocardial infarction and two missed 30 day 
events). The ESC pathway missed a similar proportion of men and women (10 men, 12 women). 
 We performed a further sensitivity analysis excluding patients with evidence of 
myocardial ischaemia on the electrocardiogram or with a GRACE score >140 (n=224), of whom 
71 patients had an index type 1 myocardial infarction. The diagnostic accuracy of both pathways 
improved. The ESC pathway still missed 13 index and one subsequent event (NPV 98.3% [95% 
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CI, 97.3-99.0%]), whereas the High-STEACS pathway missed only one index and one 
subsequent event (NPV 99.7% [95% CI, 99.2-99.9%] P<0.001). 
We evaluated the diagnostic performance of both pathways for a composite endpoint 
incorporating an index diagnosis of type 1 or type 2 myocardial infarction, or myocardial injury, 
or myocardial infarction or cardiac death at 30 days. The High-STEACS pathway missed an 
additional five events, whilst the ESC pathway missed an additional nine events (High-STEACS 
NPV 99.0% [95% CI, 98.2-99.5%], nine false negatives; two index type 1 and five index type 2 
myocardial infarction, two type 1 myocardial infarction at 30 days, versus ESC NPV 96.9%
[95% CI, 95.8-97.9%], 29 false negatives; 18 index type 1 and nine index type 2 myocardial 
infarction, two type 1 myocardial infarction at 30 days, respectively).  
Discussion
In patients with suspected acute coronary syndrome, we describe a clinical pathway utilising low 
cardiac troponin concentrations within the reference range to risk stratify patients. This approach 
identifies more patients as low risk at presentation, and has a better overall negative predictive 
value than guideline approved pathways based solely on the 99th centile. Implementation of this 
pathway has the potential to improve the efficiency and safety of early rule-out approaches for 
patients with suspected acute coronary syndrome. 
We make a number of important and clinically relevant observations. First, we 
demonstrate the High-STEACS pathway misses fewer patients with an index diagnosis of 
myocardial infarction, or myocardial infarction or cardiac death events at 30 days than the 
pathway approved by the European Society of Cardiology (4 missed events versus 20 missed 
events). Second, the negative predictive value of our pathway is 99.5% and better than the 
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existing ESC pathway across all pre-specified subgroups. In particular, the ESC pathway was 
less effective in men, those with a history of ischaemic heart disease, and those presenting early 
after the onset of symptoms. Third, in patients without an elevated troponin concentration at 
presentation, the High-STEACS pathway identified half as low risk with a single measurement, 
compared to a third identified using the established pathway. This is despite being safer, and 
missing fewer patients with an index myocardial infarction.  
 The European Society of Cardiology guideline recommends the use of high-sensitivity 
cardiac troponin assays, and their central algorithm advises the 99th centile be used as the 
threshold to rule in and rule out myocardial infarction at presentation and at three hours.6
However, the 99th centile may not be the optimal threshold to rule out myocardial infarction, and 
our observations suggest this threshold does not provide an acceptable NPV or sensitivity (97.9%
[95%CI 96.9-98.7%] and 89.3% [95%CI 84.9-93.5%] respectively). The performance of the 
ESC pathway is improved by inclusion of a risk stratification threshold and recognition that 
changes in cardiac troponin concentration within the reference range are important. In a large
external validation cohort, we report that more than two-thirds of patients with troponin 
concentrations above our risk stratification threshold at presentation can be safely ruled out at 3 
hours if troponin concentrations are unchanged (<3 ng/L), with no missed diagnosis of type 1 
myocardial infarction.  
 Our findings are consistent with a recently published evaluation of the ESC pathway 
which reported a negative predictive value of 99.0% [95%CI 98.1-99.5%], and sensitivity of 
93.2% [95%CI 87.5-96.8%] in a pooled analysis of five international cohorts.22 Importantly, this 
analysis included lower risk patients without ischaemia on the electrocardiogram. In practice, 
risk stratification and early rule-out pathways are only likely to be applied to patients without 
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overt myocardial ischaemia on the electrocardiogram.25 However, interpretation of the 
electrocardiogram may be subjective and dependent on clinician experience, and therefore we 
included all patients in our evaluation to ensure our safety estimates were conservative. 
Likewise, many clinicians use risk stratification tools to identify patients suitable for early 
discharge. Whilst the ESC guidelines do not advocate use of GRACE score for this purpose, it is 
widely used and is recommended to guide further investigation in patients whom myocardial 
infarction has been ruled out. When we restricted our analysis to patients with no significant ST-
segment depression or T-wave inversion on the electrocardiogram and GRACE scores of <140, 
we observed a modest improvement in the NPV of the ESC pathway (98.3% [95% CI, 97.3-
99.0%]), although even in this lower risk group the ESC pathway was inferior to the High-
STEACS pathway (NPV 99.7% [95% CI, 99.2-99.9%]). Whilst the inclusion of all patients in 
the primary analysis ensures our safety estimates are conservative, it is important to highlight 
that in clinical practice, careful clinical assessment and risk assessment is mandatory for all 
diagnostic pathways. In implementing our pathway, we recommend that patients with overt 
myocardial ischemia on the electrocardiogram at presentation are admitted for further assessment 
(Figure S2).
Pickering and colleagues utilized a single diagnostic threshold for myocardial infarction 
(26 ng/L) in both men and women, although a sensitivity analysis showed the performance of the 
ESC pathway was similar using sex-specific thresholds.22 In our analysis, we observed a 
reduction in the performance of the ESC pathway in men evaluated using the same assay with 
sex-specific thresholds (34 ng/L in men, 16 ng/L in women; 15 missed events and 5 missed 
events, respectively). In our sensitivity analysis, use of a single diagnostic threshold of 26 ng/L 
in men and women did not improve the overall performance of the ESC pathway. In contrast, the 
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safety of the High-STEACS pathway was robust across both sexes and all pre-specified 
subgroups of patients. Whilst the use of sex-specific thresholds in pathways that rely on the 99th
centile remains contentious in clinical practice, risk stratification thresholds are not influenced by 
sex,14 and therefore a single threshold can be applied equally to risk stratify men and women at 
presentation.  
 The efficacy of early rule-out pathways is also an important consideration. We 
demonstrate that the High-STEACS pathway ruled out a higher proportion of patients than the 
ESC pathway at presentation (40.7% versus 28.1%, P<0.001). Whilst our pathway rules out 
fewer patients at 3 hours (74.2% versus 78.9%), P<0.001), of the additional 57 patients ruled out 
by the ESC pathway, 1 in 5 (22.8%) were incorrectly ruled out and had an index diagnosis of 
type 1 myocardial infarction identified on subsequent testing. By identifying those patients with 
a change in cardiac troponin concentration QJ/IURPSUHVHQWDWLRQWRthree hours and 
undertaking further testing, none of these events would be missed by the High-STEACS 
pathway. This highlights the value of high-sensitivity cardiac troponin assays, which permit the 
identification of small, but important changes in troponin concentration within the normal 
reference range, and allow refinement in the risk stratification of patients with suspected acute 
coronary syndrome. The only disadvantage of our pathway is that in prioritising safety, the 
specificity and PPV for a diagnosis of myocardial infarction is lower than the ESC pathway at 3 
hours (4% and 7% respectively). Specificity is also important, but in our view it need not be 
prioritized in early rule out pathways. In patients we identify who require hospital admission, the 
diagnosis of myocardial infarction is best determined by demonstrating a rise and fall in cardiac 
troponin concentration over 6-12 hours. 
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 The latest ESC guidelines have introduced a one-hour pathway that incorporates a risk 
stratification step utilising high-sensitivity cardiac troponin concentrations within the reference 
range.6 This approach shows promise, and has been validated using both high sensitivity 
troponin I and high sensitivity troponin T assays, with a NPV of 99.6% [95% CI, 98.4-100] and 
99.1% [95% CI, 98.2-99.7%] respectively.18,19 However, to our knowledge no previous studies 
have directly compared pathways that utilise a risk stratification step with low cardiac troponin 
concentrations to those based exclusively on the 99th centile. Further studies are needed to 
compare the efficacy and safety of retesting at 1 and 3 hours in pathways that incorporate a risk 
stratification threshold.  
 One of the limitations of these studies, including our own, is that they are observational 
in nature, and enrol selected patients rather than all consecutive patients. Indeed, as no patients 
were discharged on the basis of pathway decisions, the true efficacy and safety of this approach 
is unknown. The ESC pathway recommends repeat testing in patients who present within 6 hours 
of symptom onset. Whilst the inclusion of patients who present early is a strength of our study, 
fewer patients may be ruled out at presentation by the ESC pathway as a consequence. At 
present, clinicians do not have evidence from prospective randomised controlled trials to inform 
their practice.29 As such, we are conducting a multi-centred stepped-wedge cluster randomised
trial to determine the efficacy and safety of our pathway (Figure S2) in unselected consecutive 
patients across Scotland. The outcome of this trial will help to inform our practice, and provide 
an evidence base for future recommendations on the use of high-sensitivity cardiac troponins to 
risk stratify patients with suspected acute coronary syndrome.  
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Conclusions
The High-STEACS pathway, incorporating low cardiac troponin concentrations to risk stratify 
patients, rules out more patients on presentation and misses fewer index or recurrent myocardial 
infarction than guideline-approved pathways based exclusively on the 99th centile.
Implementation of this pathway has the potential to improve the efficiency and safety of early 
rule out approaches for patients with suspected acute coronary syndrome.
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Table 1. Baseline demographics stratified by cardiac troponin concentration at presentation
All Patients
(n=1,218)
hs-cTnI
<5ng/L 
(n=692)
hs-cTnI
99th centile 
(n=1,002)
hs-cTnI
>99th centile
(n=216)
P-value
Age 62.36 (14.1) 57.1 (12.3) 60.97 (13.8) 68.78 (14.1) <0.001
Male (%) 742 (60.9) 383 (55.3) 622 (62.1) 120 (55.6) 0.088
Primary Symptom
Chest Pain 1044 (85.7) 614 (88.7) 873 (87.1) 171 (79.2) <0.001
Collapse 13 (1.1) 7 (1.0) 8 (0.8) 5 (2.3) 0.578
Dyspnoea 40 (3.3) 10 (1.4) 25 (2.5) 15 (6.9) 0.151
Palpitations 20 (1.6) 7 (1.0) 15 (1.5) 5 (2.3) 0.043
Symptom onset 
Minutes since onset 208 (116-616) 196 (111-688) 198 (112-594) 249 (130-744) 0.032
< 2 hours (%) 326 (26.8) 196 (28.4) 279 (27.9) 47 (21.8) 0.081
DQGKRXUV 463 (38.0) 250 (36.1) 381 (38.0) 82 (38.0) 1.000
KRXUV 429 (35.2) 246 (35.5) 342 (34.1) 87 (40.3) 0.102
Cardiovascular Risk Factors
Smoker (%) 255 (20.9) 174 (25.1) 217 (21.7) 38 (17.6) 0.385
Diabetes mellitus (%) 184 (15.6) 75 (11) 140 (14.4) 44 (21.0) 0.024
Hypertension (%) 550 (47.2) 255 (38.4) 443 (46.3) 107 (51.4) 0.203
Hyperlipidaemia (%) 493 (43.3) 233 (33.5) 402 (42.9) 91 (44.8) 0.681
Family history (%) 569 (51.5) 350 (53.8) 479 (52.2) 90 (47.9) 0.312
Known angina (%) 409 (34.6) 180 (26.5) 334 (34.2) 75 (36.4) 0.597
Previous MI (%) 308 (26.1) 112 (16.5) 244 (25.2) 64 (30.6) 0.124
Previous PCI (%) 248 (21.3) 110 (16.4) 205 (21.4) 43 (20.9) 0.942
Previous CABG (%) 87 (7.5) 24 (3.9) 71 (7.5) 16 (7.8) 0.995
Heart failure (%) 42 (3.7) 4 (0.6) 25 (2.7) 17 (8.7) <0.001
Stroke (%) 81 (7.0) 26 (3.9) 63 (6.6) 18 (8.8) 0.337
Peripheral vascular disease (%) 29 (2.6) 7 (1.1) 21 (2.2) 8 (4.0) 0.225
Admission Medication
Aspirin (%) 442 (38.3) 210 (31.4) 361 (38.0) 81 (39.7) 0.707
Clopidogrel (%) 150 (13.5) 61 (9.5) 119 (13.1) 31 (15.6) 0.409
Warfarin (%) 84 (7.7) 25 (4.0) 66 (7.4) 18 (9.0) 0.52
Beta blocker (%) 353 (31.6) 159 (24.8) 286 (31.2) 67 (33.5) 0.587
ACEi or ARB (%) 379 (33.9) 170 (26.5) 306 (33.3) 73 (36.7) 0.405
CCB (%) 158 (14.4) 72 (11.4) 128 (14.2) 30 (15.2) 0.822
Statin (%) 540 (46.9) 253 (38.4) 444 (46.8) 96 (47.5) 0.91
Values are number (%) or mean (SD) or median (inter-quartile range). 
Abbreviations: ACE = angiotensin converting enzyme; ARB = angiotensin receptor blocker;  MI = 
myocardial infarction; CCB = calcium channel blocker; PCI = percutaneous coronary intervention; 
CABG = coronary artery bypass grafting
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Table 2. Diagnostic performance of ESC pathway and High-STEACS pathway for the primary outcome at three hours
TP FP TN FN NPV(Mean, 95% CI)
PPV
(Mean, 95% CI)
Sensitivity
(Mean, 95%CI)
Specificity
(Mean, 95%CI)
All patients
(n=1,218) 
High-STEACS 187 127 900 4 99.5 (99.0-99.9) 59.5 (54.1-64.9) 97.7 (95.5-99.5) 87.6 (85.6-89.6)
ESC pathway 171 86 941 20 97.9 (96.9-98.7) 66.5 (60.6-72.1) 89.3 (84.9-93.5) 91.6 (89.9-93.3) 
Subgroup analysis
<3 hours since onset
(n=544)
High-STEACS 81 60 402 1 99.6 (98.8-100) 57.4 (49.2-65.4) 98.2 (95.3-100) 86.9 (83.8-89.9) 
ESC pathway 73 43 419 9 97.8 (96.2-99.0) 62.8 (53.9-71.3) 88.6 (81.6-94.9) 90.6 (87.9-93.2) 
<6 hours since onset
(n=789)
High-STEACS 117 98 572 2 99.6 (98.9-99.9) 54.4 (47.7-61.0) 97.9 (95.4-99.9) 85.3 (82.6-88.0) 
ESC pathway 104 66 604 15 97.5 (96.1-98.6) 61.1 (53.7-68.3) 87.1 (81.0-92.8) 90.1 (87.8-92.3) 
>6 hours since onset
(n=429) 
High-STEACS 70 29 328 2 99.2 (98.1-99.9) 70.5 (61.2-79.0) 96.6 (92.4-99.8) 91.8 (88.9-94.5)
ESC pathway 67 20 337 5 98.4 (96.8-99.4) 76.7 (67.4-84.9) 92.5 (86.4-97.8) 94.3 (91.8-96.6) 
Men
(n=742) 
High-STEACS 122 73 544 3 99.4 (98.5-99.8) 62.5 (55.6-69.1) 97.2 (94.4-99.6) 88.1 (85.5-90.6) 
ESC pathway 110 38 579 15 97.4 (96.0-98.5) 74.2 (66.9-80.8) 87.7 (81.9-93.2) 93.8 (91.8-95.6)
Women 
(n=476) 
High-STEACS 65 54 356 1 99.6 (98.7-100) 54.6 (45.7-63.4) 97.8 (94.2-100) 86.7 (83.4-90.0) 
ESC pathway 61 48 362 5 98.5 (97.0-99.5) 55.9 (46.6-65.0) 91.8 (85.2-97.6) 88.2 (85.0-91.2)
TP FP TN FN NPV(Mean, 95% CI)
PPV
(Mean, 95% CI)
Sensitivity
(Mean, 95%CI)
Specificity
(Mean, 95%CI)
Subgroup analysis (continued)
Age <65 years 
(n=701)
High-STEACS 78 39 583 1 99.7 (99.2-100) 66.5 (57.8-74.7) 98.1 (95.1-100) 93.7 (91.7-95.5)
ESC pathway 72 29 593 7 98.8 (97.7-99.5) 71.1 (62.0-79.4) 90.6 (84.2-96.5) 95.3 (93.6-96.9) 
$JH\HDUV
(n=517)
High-STEACS 109 88 317 3 98.9 (97.5-99.7) 55.3 (48.4-62.2) 96.9 (93.7-99.5) 78.2 (74.2-82.2) 
ESC pathway 99 57 348 13 96.3 (94.1-98.0) 63.4 (55.7-70.7) 88.1 (82.0-93.7) 85.8 (82.4-89.2) 
High-STEACS 85 77 352 4 98.7 (97.4-99.6) 52.5 (44.8-60.1) 90.5 (90.5-98.9) 82.0 (78.3-85.6) 
 by guest on January 12, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.116.025021
26
Known ischaemic heart 
disease 
(n=518) 
ESC pathway 73 52 377 16 95.8 (93.6-97.6) 58.3 (49.6-66.8) 81.7 (73.6-89.3) 87.8 (84.7-90.8) 
No known ischaemic heart 
disease 
(n=680)
High-STEACS 99 48 533 0 99.9 (99.6-100) 67.2 (59.5-74.5) 99.5 (98.1-100) 91.7 (89.4-93.9) 
ESC pathway 95 33 548 4 99.2 (98.3-99.8) 74.0 (66.2-81.2) 95.5 (91.4-99.0) 94.2 (92.3-96.1) 
Abbreviations: TP = True Positive, FP = False Positive, TN = True Negative, FN = False Negative, NPV = Negative Predictive Value, 
PPV = positive predictive value
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Figure Legends
Figure 1. Summary of the ESC (A) and High-STEACS (B) rule out pathways for myocardial 
infarction. Percentages indicate number of patients ruled in or out at a given time point, as a 
proportion of the analysis population (n=1,218).  
*In the High-STEACS pathway, patients with cardiac troponin concentrations <5 ng/L who 
present within two hours of symptom onset are retested at three hours.  
Figure 2. Negative predictive value for index type 1 myocardial infarction, or myocardial 
infarction or cardiac death at 30 days of conventional and High-STEACS pathways. Forest plot 
of the negative predictive value and 95% confidence intervals of the High-STEACS pathway 
(red) and the ESC pathway (blue) stratified by pre-specified subgroups. Numbers are true 
negative, false negative and negative predictive value (95% confidence intervals). The vertical 
dashed line (red) highlights the central estimate of the negative predictive value of the High-
STEACS pathway in the total population. 
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Table S1 – Baseline characteristics for the APACE external validation cohort 
 APACE Study*  
(n=2,533) 
Age  61 (16.0) 
Male (%) 1,722 (68.0) 
Primary Symptom  
   Chest Pain 2,214 (87.4) 
Symptom onset   
   Minutes since onset  300 (120-720) 
   Less than three hours (%) 717 (28.5) 
   Less than six hours (%) 1,338 (53.2) 
   Over six hours (%) 1,054 (41.9) 
Cardiovascular Risk Factors  
   Smoker (%) 635 (25.1) 
   Diabetes mellitus (%) 451 (17.8) 
   Hypertension (%) 1,591 (62.8) 
   Hyperlipidaemia (%) 1,293 (51.0) 
   Family history (%) 987 (40.9) 
   Known angina (%) 883 (34.9) 
   Previous MI (%) 621 (24.5) 
   Previous PCI (%) 646 (25.5) 
   Previous CABG (%) 228 (9.0) 
   Stroke (%) 149 (5.9) 
   Peripheral vascular disease (%) 146 (5.8) 
Troponin concentration at presentation  
   <5 ng/L (%) 1,348 (53.2) 
   ≥5 ng/L and ≤ 99th centile (%) 735 (29.0) 
   >99th centile (%) 450 (17.8) 
Adjudicated Diagnosis  
   Type 1 myocardial infarction (%) 289 (11.4) 
   All myocardial infarction (%) 378 (14.9) 
	 3 
  
*The APACE study is a prospective cohort study of patients with suspected acute coronary 
syndrome presenting to the Emergency Department of Basel and six other centers in Europe 
between April 2006 and August 2015.  Blood samples were obtained on presentation and at 3, 
and 6h for high-sensitivity cardiac troponin I testing. All diagnoses were adjudicated by two 
independent cardiologists; the diagnosis of type 1 myocardial infarction required at least one 
high-sensitivity cardiac troponin I concentration above the sex-specific 99th centile upper 
reference limit (16 ng/L women, 34 ng/L men). This study was approved by the local ethics 
committee. 
 
 
  
 
	 4 
Table S2. Patients ruled out by the ESC pathway at 0 and 3 hours meeting the primary outcome  
Age Gender Time since 
symptom onset 
(Minutes) 
Troponin 
concentration, 
ng/L (hours) 
Relative 
Change (%) 
Absolute 
Change  
Presenting 
Symptom 
Index Diagnosis Risk Factors Initial ECG Management 
81 Male 444 31 (0) 
33 (3) 
39 (12) 
6.5 2 Chest Pain Type 1 MI Hypertension 
Hyperlipidaemia 
Ischaemic Heart Disease 
Previous CABG 
Sinus Rhythm 
ST Depression 
T wave Inversion 
PCI to LCx 
57 Male 440 33 (0) 
80 (3) 
144 (5) 
 
142.4 47 Chest Pain Type 1 MI Previous Smoker 
Family History of CHD 
Sinus Rhythm 
 
PCI to OM1 
70 Male 375 17 (0) 
160 (3) 
2583 (6) 
841.2 143 Chest Pain Type 1 MI Previous Smoker 
Diabetes 
Hypertension 
Hyperlipidaemia 
Previous MI 
Sinus Rhythm 
RBBB 
Medical  
84 Male 4900 25 (0) 
44 (3) 
76.0 19 Chest Pain Type 1 MI Hypertension 
Previous MI 
Previous PCI 
Previous CABG 
Previous Stroke 
Atrial Fibrillation PCI to SVG-D1 
82 Female 86 11 (0) 
15 (3) 
26 (10) 
 
36.4 4 Chest Pain Type 1 MI Hypertension Sinus Rhythm Medical 
62 Male 70 27 (0) 
32 (3) 
50 (11) 
18.5 5 Chest Pain Type 1 MI Current Smoker 
Diabetes 
Hypertension 
Hyperlipidaemia 
Previous MI 
Previous PCI 
Sinus Rhythm Medical 
87 Male 139 5 (0) 
16 (3) 
691 (10) 
220.0 11 Chest Pain Type 1 MI Previous Smoker 
Hypertension 
Ischaemic Heart Disease 
Previous CABG 
Atrial Fibrillation 
ST Depression 
 
Medical 
	 5 
73 Male 180 26 (0) 
29 (3) 
41 (9) 
11.5 3 Chest Pain Type 1 MI Previous Smoker 
Hypertension 
Hyperlipidaemia 
Family history of CHD 
Previous MI 
Previous CABG 
Sinus Rhythm 
LBBB 
Medical 
58 Male 122 26 (0) 
33 (3) 
46 (11) 
26.9 7 Dyspnoea Type 1 MI Previous Smoker 
Diabetes 
Family history of CHD 
Ischaemic Heart Disease 
Previous MI 
Previous CABG 
Previous Stroke 
Sinus Rhythm 
T wave inversion 
Medical 
63 Female 151 10 (0) 
16 (3) 
167 (10) 
60.0 6 Chest Pain Type 1 MI Current Smoker 
Family history of CHD 
Sinus Rhythm 
ST Depression  
PCI to LAD 
66 Male 89 12 (0) 
31 (3) 
202 (10) 
158.3 19 Chest Pain Type 1 MI Hypertension 
Previous MI 
Previous PCI 
Sinus Rhythm Medical 
60 Male 81 2 (0) 
6 (3) 
2932 (11) 
200.0 4 Chest Pain Type 1 MI Current Smoker 
Family History of CHD 
Ischaemic Heart Disease 
Previous PCI 
Sinus Rhythm 
T wave inversion 
(old) 
PCI to RCA/D1 
56 Male 262 8 (0) 
14 (3) 
307 (10) 
75.0 6 Chest Pain Type 1 MI Previous Smoker 
Hypertension 
Hyperlipidaemia 
Family history of CHD 
Ischaemic Heart Disease 
Previous MI 
Previous PCI 
Sinus Rhythm Medical 
77 Male 272 21 (0) 
26 (3) 
56 (10) 
23.8 5 Chest Pain Type 1 MI Previous Smoker 
Diabetes 
Hypertension 
Hyperlipidaemia 
Family history of CHD 
Previous MI 
Previous PCI 
Atrial Fibrillation 
Inferior Q waves  
Medical 
66 Male 305 22 (0) 
36 (3) 
63.6 14 Chest Pain Type 1 MI Ischaemic Heart Disease 
Hypertension 
Sinus Rhythm 
Bradycardia 
PCI to LCx 
Instent Restenosis 
	 6 
50 (8) 
 
Hyperlipidaemia 
Previous MI 
Previous PCI 
60 Male 295 14 (0) 
14 (3) 
170 (8) 
0 0 Chest Pain Type 1 MI Current Smoker 
Hypertension 
Hyperlipidaemia 
Family history of CHD 
Ischaemic heart disease 
Previous MI 
Sinus Rhythm 
Bradycardia 
Angiography 
70% stenosis OM1 
Medical  
88 Female 222 15 (0) 
19 (3) 
26.7 4 Chest Pain Type 1 MI Ischaemic heart disease 
Previous MI 
Previous PCI 
Family history of CHD 
Sinus Rhythm Medical 
89 Female 165 16 (0) 
18 (3) 
24 (10) 
12.5 2 Chest Pain Type 1 MI Hypertension 
Family history of CHD 
Ischaemic Heart Disease 
Sinus Rhythm Medical 
82 Male 126 19 (0) 
20 (3) 
22 (11) 
 
Re-attendance 
 
52 (0) 
44 (3) 
24 (10) 
5.3 1 Chest Pain Musculoskeletal 
Chest Pain 
Previous Smoker 
Diabetes 
Hyperlipidaemia 
Family history of CHD 
Ischaemic Heart Disease 
Previous MI 
Previous CABG 
Sinus Rhythm 
First Degree HB 
Left Axis Deviation 
RBBB 
 
Re-presented with 
ongoing chest pain 
two days post index 
presentation 
 
Missed Type 1 MI 
  
73 Female 425 9 (0) 
11 (3) 
  
22.2 2 Chest Pain Paroxysmal AF Previous Smoker 
Hypertension 
Hyperlipidaemia 
Ischaemic Heart Disease 
Previous MI 
Previous PCI 
Atrial Fibrillation 
RBBB 
T wave inversion 
Re-presented with 
inferior STEMI 14 
days post index 
presentation 
 
PCI to RCA 
 
Type 1 MI 
 
Demarcations for missed index events with ≥6 hours symptoms (n=4), <6 hours symptoms (n=14) and 30 day events (n=2) 
AF = atrial fibrillation, CABG = coronary artery bypass graft, CHD = coronary heart disease, LBBB = left bundle branch block, RBBB = right bundle branch block, MI = myocardial infarction, PCI = percutaneous 
coronary intervention, STEMI = ST-segment elevation myocardial infarction.  
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Table S3. Patients ruled out by the High-STEACS pathway at 0 and 3 hours meeting the primary outcome 
Age Gender Time since 
symptom onset 
(Minutes) 
Troponin 
concentration, 
ng/L (hours) 
Relative 
Change (%) 
Absolute 
Change  
Presenting 
Symptom 
Index Diagnosis Risk Factors Initial ECG Management 
81 Male 444 31 (0) 
33 (3) 
39 (12) 
6.45 2 Chest Pain Type 1 MI Hypertension 
Hyperlipidaemia 
Ischaemic Heart Disease 
Previous CABG 
Sinus Rhythm 
ST Depression 
T wave Inversion 
PCI to LCx 
60 Male 295 14 (0) 
14 (3) 
170 (8) 
0 0 Chest Pain Type 1 MI Current Smoker 
Hypertension 
Hyperlipidaemia 
Family history of CHD 
Ischaemic heart disease 
Previous MI 
Sinus Rhythm 
Bradycardia 
Angiography 
70% stenosis OM1 
Medical 
82 Male 126 19 (0) 
20 (3) 
22 (11) 
 
Re-attendance 
 
52 (0) 
44 (3) 
24 (10) 
5.3 1 Chest Pain Musculoskeletal 
Chest Pain 
Previous Smoker 
Diabetes 
Hyperlipidaemia 
Family history of CHD 
Ischaemic Heart Disease 
Previous MI 
Previous CABG 
Sinus Rhythm 
First Degree HB 
Left Axis Deviation 
RBBB 
 
Re-presented with 
ongoing chest pain 
two days post index 
presentation 
 
Missed Type 1 MI 
 
73 Female 425 9 (0) 
11 (3) 
  
 
22.2 2 Chest Pain Paroxysmal AF Previous Smoker 
Hypertension 
Hyperlipidaemia 
Ischaemic Heart Disease 
Previous MI 
Previous PCI 
Atrial Fibrillation 
RBBB 
T wave inversion 
Re-presented with  
inferior STEMI 
14 days post index 
presentation 
 
PCI to RCA 
 
Type 1 MI 
 
Demarcation for missed index events (n=2) and 30 day events (n=2) 
AF = atrial fibrillation, CABG = coronary artery bypass graft, CHD = coronary heart disease, LBBB = left bundle branch block, RBBB = right bundle branch block, MI = myocardial infarction, PCI = percutaneous 
coronary intervention. STEMI = ST-segment elevation myocardial infarctioz
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Table S4 – 2x2 table for internal validation of delta criteria at three hours 
 
  
 Type 1 MI No Type 1 MI 
 
Change ≥3 ng/L at 3 hours 
 
40 52 
 
Change <3 ng/L at 3 hours 
 
2 216 
 
 
Patients with cardiac troponin concentrations ≥5 ng/L and <99th centile on presentation are re-
tested at three hours. Those with a change in cardiac troponin of <3 ng/L are ruled out if they 
remain <99th centile. 
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Table S5 – 2x2 table for external validation of delta criteria at three hours 
 
  
 Type 1 MI No Type 1 MI 
 
Change ≥3 ng/L at 3 hours 
 
51 170 
 
Change <3 ng/L at 3 hours 
 
0 514 
 
 
Patients with cardiac troponin concentrations ≥5 ng/L and <99th centile on presentation are re-
tested at three hours. Those with a change in cardiac troponin of <3 ng/L are ruled out if they 
remain <99th centile. 
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Table S6 – 2x2 table with diagnostic performance of the High-STEACS pathway at 6 hours 
 
 
 Type 1 MI No Type 1 MI 
 
Pathway rules in 
 
187 88 
 
Pathway rules out 4 939 
 
 
Patients with cardiac troponin concentrations <5 ng/L who present over two hours from time of 
symptom onset are ruled out on presentation. Those ≥5 ng/L and <99th centile on presentation, and 
those who present within two hours of symptom onset are re-tested at three hours. Those with a 
change in cardiac troponin of <3 ng/L are ruled out if they remain <99th centile, with all other 
patients admitted for peak testing at six hours.  
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Study Population (n=1,292)
Presentation hsTnI result 
≤99th centile
(n=1,002)
Presentation hsTnI result 
>99th centile
(n=216)
Adjudicated Diagnosis
Type 1 MI (n=44)
Type 2 MI (n=21)
Myocardial Injury (n=1)
Adjudicated Diagnosis
Type 1 MI (n=145)
Type 2 MI (n=46)
Myocardial Injury (n=25)
30 day outcomes
Subsequent Type 1 MI (n=4)
Cardiac Death (n=5)
30 day outcomes
Subsequent Type 1 MI (n=2)
Cardiac Death (n=1)
Analysis Population (n=1,218)
Exclusions
Patients without serial sample (n=74)
Figure S1.  Study population, adjudicated diagnosis and 30 day outcomes  
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Figure S2.  Diagnostic algorithm of the High-STEACS pathway 
 
	
 
 
Diagnostic algorithm of the High-STEACS pathway, currently being evaluated as part of a multi-
centre stepped-wedge cluster randomised trial in unselected consecutive patients across Scotland. 
*In the High-STEACS pathway, patients with cardiac troponin concentrations <5 ng/L who present 
within two hours of symptom onset are retested at three hours.  
 
Symptoms	≥	2	hours
AND
<5	ng/L
>16	ng/L	(women)
>34	ng/L	(men)
CHANGE	<3	ng/L
AND
≤16	ng/L	(women)
≤34	ng/L	(men)
≤16	ng/L	(women)
≤34	ng/L	(men)
≥5	ng/L AND
≤16	ng/L	(women)
≤34	ng/L	(men)
>16	ng/L	(women)
>34	ng/L	(men)
CHANGE	≥3	ng/L
AND
≤16	ng/L	(women)
≤34	ng/L	(men)
Admit	and	hs-cTnI	6	hours	from	presentation
>16	ng/L	(women)
>34	ng/L	(men)
RULE	OUT	M
YOCARDIAL	INFARCTION	/	INJURY
ADM
IT	W
ITH	M
YOCARDIAL	INFARCTION	/	INJURY
Repeat	hs-cTnI	3	hours	from	presentation
Suspected	acute	coronary	 syndrome
Electrocardiogram	 with	clinical	
assessment	and	high-sensitivity	
cardiac	troponin	 I	(hs-cTnI)
Diagnostic	ECGNon- diagnostic	 ECG
Admit	and	hs-cTnI	at	6	hReview	hs-cTnI	at	presentation
*
